[{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"7137bb56-9c9c-4ff1-bf66-4a2cdf70604f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620187","created_at":"2021-01-19T20:34:19.621Z","updated_at":"2025-02-25T14:07:59.706Z","phase":"Phase 2","brief_title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","source_id_and_acronym":"NCT04620187","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-18"},{"id":"0a44475b-ada6-49fd-a78d-da7cabf4adaa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02879162","created_at":"2021-01-18T14:08:03.022Z","updated_at":"2025-02-25T14:14:51.028Z","phase":"Phase 2","brief_title":"Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT02879162","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 06/20/2021","primary_completion_date":" 06/20/2021","study_txt":" Completion: 01/29/2025","study_completion_date":" 01/29/2025","last_update_posted":"2025-02-17"},{"id":"fa762180-1ac0-4c2f-bfff-1035ccc3f515","acronym":"","url":"https://clinicaltrials.gov/study/NCT05669664","created_at":"2023-12-04T19:35:23.503Z","updated_at":"2025-02-25T15:20:12.831Z","phase":"Phase 2","brief_title":"Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers","source_id_and_acronym":"NCT05669664","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 04/11/2027","primary_completion_date":" 04/11/2027","study_txt":" Completion: 04/11/2027","study_completion_date":" 04/11/2027","last_update_posted":"2025-02-12"},{"id":"a8e4ef32-1344-482b-a5f5-187c3f5e9c87","acronym":"YATAGARASU","url":"https://clinicaltrials.gov/study/NCT04325828","created_at":"2021-01-18T20:57:18.226Z","updated_at":"2025-02-25T15:26:19.647Z","phase":"Phase 2","brief_title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","source_id_and_acronym":"NCT04325828 - YATAGARASU","lead_sponsor":"Janssen Pharmaceutical K.K.","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 06/09/2021","primary_completion_date":" 06/09/2021","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-10"},{"id":"e55df251-1fde-47bd-86f1-be2ff4bd4e5a","acronym":"VISTA","url":"https://clinicaltrials.gov/study/NCT03740256","created_at":"2021-01-18T18:19:18.650Z","updated_at":"2025-02-25T16:31:39.867Z","phase":"Phase 1","brief_title":"Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors","source_id_and_acronym":"NCT03740256 - VISTA","lead_sponsor":"Baylor College of Medicine","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT16"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 12/14/2020","start_date":" 12/14/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2038","study_completion_date":" 12/30/2038","last_update_posted":"2025-02-07"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"204a3645-717f-42ed-9810-3a60efcecc4a","acronym":"BTCRC-HN17-111","url":"https://clinicaltrials.gov/study/NCT03942653","created_at":"2021-01-18T19:24:28.517Z","updated_at":"2025-02-25T16:09:07.413Z","phase":"Phase 2","brief_title":"Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma","source_id_and_acronym":"NCT03942653 - BTCRC-HN17-111","lead_sponsor":"Manish Patel","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/30/2019","start_date":" 05/30/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-10-11"},{"id":"03fa7b60-29a0-4a44-aa05-14a8b5df45eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02091141","created_at":"2021-01-17T17:15:36.027Z","updated_at":"2025-02-25T12:26:06.921Z","phase":"Phase 2","brief_title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02091141","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • erlotinib • Zelboraf (vemurafenib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 673","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-07-23"},{"id":"893db886-c712-4cce-b597-bb3b00601a44","acronym":"DISCOVARY","url":"https://clinicaltrials.gov/study/NCT05694819","created_at":"2023-01-23T14:59:43.274Z","updated_at":"2025-02-25T17:25:58.308Z","phase":"Phase 2","brief_title":"Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)","source_id_and_acronym":"NCT05694819 - DISCOVARY","lead_sponsor":"National Cancer Center Hospital East","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nubeqa (darolutamide) • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/17/2020","start_date":" 04/17/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-06-21"},{"id":"15ebc24f-836d-4955-b1c1-9b9491f8cda7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04895735","created_at":"2021-05-20T11:54:07.989Z","updated_at":"2024-07-02T16:34:26.348Z","phase":"Phase 2","brief_title":"Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer","source_id_and_acronym":"NCT04895735","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • MTAP • TYMS","pipe":" | ","alterations":" PD-L1 expression • TYMS expression","tags":["PD-L1 • MTAP • TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TYMS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/23/2021","start_date":" 07/23/2021","primary_txt":" Primary completion: 06/03/2025","primary_completion_date":" 06/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2024-06-13"},{"id":"80611a75-8e50-4af0-8595-0b4412326e20","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576091","created_at":"2021-01-18T21:50:45.107Z","updated_at":"2024-07-02T16:34:37.303Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer","source_id_and_acronym":"NCT04576091","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • elimusertib (BAY 1895344) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 11/27/2024","primary_completion_date":" 11/27/2024","study_txt":" Completion: 11/27/2024","study_completion_date":" 11/27/2024","last_update_posted":"2024-06-07"},{"id":"74b7f5ec-f76b-4d4d-94ea-2b07dca4fa42","acronym":"iPRIME","url":"https://clinicaltrials.gov/study/NCT03360890","created_at":"2021-01-18T16:35:19.786Z","updated_at":"2024-07-02T16:35:02.340Z","phase":"Phase 2","brief_title":"Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors","source_id_and_acronym":"NCT03360890 - iPRIME","lead_sponsor":"University of Chicago","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/26/2018","start_date":" 03/26/2018","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2024-05-21"},{"id":"4f044f18-3e23-4009-90ad-d13973fbf09d","acronym":"KEYNOTE-158","url":"https://clinicaltrials.gov/study/NCT02628067","created_at":"2021-01-17T17:22:08.805Z","updated_at":"2024-07-02T16:35:04.350Z","phase":"Phase 2","brief_title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","source_id_and_acronym":"NCT02628067 - KEYNOTE-158","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 1609","initiation":"Initiation: 12/18/2015","start_date":" 12/18/2015","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2024-05-10"},{"id":"acac02cd-c592-4eb3-b05a-a4f2485bc521","acronym":"DUCT","url":"https://clinicaltrials.gov/study/NCT05513365","created_at":"2022-08-24T21:07:35.191Z","updated_at":"2024-07-02T16:35:07.770Z","phase":"Phase 2","brief_title":"Phase II Dutasteride in Combination With CAB vs CAB in SDC","source_id_and_acronym":"NCT05513365 - DUCT","lead_sponsor":"Radboud University Medical Center","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bicalutamide • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/27/2022","start_date":" 09/27/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-04-24"},{"id":"8214fea8-a403-48c1-9fa6-030636cc99e1","acronym":"STARTRK-2","url":"https://clinicaltrials.gov/study/NCT02568267","created_at":"2021-01-17T17:20:53.382Z","updated_at":"2024-07-02T16:35:12.401Z","phase":"Phase 2","brief_title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","source_id_and_acronym":"NCT02568267 - STARTRK-2","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ALK rearrangement • ROS1 rearrangement","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 534","initiation":"Initiation: 11/19/2015","start_date":" 11/19/2015","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-28"},{"id":"3389546b-7889-41d7-a623-1ac7e9ef8f61","acronym":"","url":"https://clinicaltrials.gov/study/NCT05924256","created_at":"2023-06-29T14:09:00.727Z","updated_at":"2024-07-02T16:35:14.639Z","phase":"Phase 2","brief_title":"A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing","source_id_and_acronym":"NCT05924256","lead_sponsor":"Fudan University","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-03-15"},{"id":"03349602-f7d4-4df1-9ca7-31fa0fc49134","acronym":"VUBAR","url":"https://clinicaltrials.gov/study/NCT03924466","created_at":"2021-01-18T19:18:22.013Z","updated_at":"2024-07-02T16:35:19.081Z","phase":"Phase 2","brief_title":"Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients","source_id_and_acronym":"NCT03924466 - VUBAR","lead_sponsor":"Universitair Ziekenhuis Brussel","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-16"},{"id":"2980bbee-f00d-4630-9f55-6aacdaeb4026","acronym":"NRG-HN010","url":"https://clinicaltrials.gov/study/NCT05408845","created_at":"2022-06-07T22:00:44.587Z","updated_at":"2024-07-02T16:35:20.570Z","phase":"Phase 2","brief_title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer","source_id_and_acronym":"NCT05408845 - NRG-HN010","lead_sponsor":"NRG Oncology","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Kadcyla (ado-trastuzumab emtansine) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2024-02-07"},{"id":"6a6417f1-7a1c-4f5d-b375-14a617d5a686","acronym":"","url":"https://clinicaltrials.gov/study/NCT04450732","created_at":"2021-01-18T21:24:44.908Z","updated_at":"2024-07-02T16:35:27.134Z","phase":"Phase 1","brief_title":"Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors","source_id_and_acronym":"NCT04450732","lead_sponsor":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GQ1001"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 07/07/2020","start_date":" 07/07/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-12-05"},{"id":"8cb1d79f-f3c5-4ab8-aae9-2a85bcc3efa0","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT05786716","created_at":"2023-03-28T14:04:56.552Z","updated_at":"2025-02-25T13:55:04.262Z","phase":"Phase 2/3","brief_title":"DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations","source_id_and_acronym":"NCT05786716 - DETERMINE","lead_sponsor":"Cancer Research UK","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/01/2029","study_completion_date":" 10/01/2029","last_update_posted":"2023-10-25"},{"id":"55fc9994-8b85-42e1-a322-c1481d787dea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03602079","created_at":"2021-01-17T17:58:25.852Z","updated_at":"2024-07-02T16:35:41.099Z","phase":"Phase 1/2","brief_title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","source_id_and_acronym":"NCT03602079","lead_sponsor":"Klus Pharma Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sertaly (trastuzumab botidotin)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 07/16/2018","start_date":" 07/16/2018","primary_txt":" Primary completion: 01/12/2022","primary_completion_date":" 01/12/2022","study_txt":" Completion: 01/12/2022","study_completion_date":" 01/12/2022","last_update_posted":"2023-08-03"},{"id":"6ac52e10-68b5-4f85-8b4c-22d47fc76b4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05898373","created_at":"2023-06-12T16:09:01.587Z","updated_at":"2024-07-02T16:35:46.018Z","phase":"Phase 2","brief_title":"Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC","source_id_and_acronym":"NCT05898373","lead_sponsor":"Peking Union Medical College","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 06/06/2025","primary_completion_date":" 06/06/2025","study_txt":" Completion: 06/06/2026","study_completion_date":" 06/06/2026","last_update_posted":"2023-06-12"},{"id":"c153810d-16f0-40f8-9439-a64b4b0d79a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01332279","created_at":"2021-01-18T05:25:50.979Z","updated_at":"2024-07-02T16:35:51.525Z","phase":"Phase 1","brief_title":"Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy","source_id_and_acronym":"NCT01332279","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" EGFR • HIF1A","pipe":" | ","alterations":" EGFR amplification • HIF1A expression • AKT1 amplification","tags":["EGFR • HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • HIF1A expression • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • everolimus"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 05/01/2011","primary_completion_date":" 05/01/2011","study_txt":" Completion: 05/01/2011","study_completion_date":" 05/01/2011","last_update_posted":"2023-04-04"}]